AJP - Renal Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 295: F1134-F1141, 2008. First published August 13, 2008; doi:10.1152/ajprenal.00104.2008
0363-6127/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/4/F1134    most recent
00104.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sánchez-Lozada, L. G.
Right arrow Articles by Johnson, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sánchez-Lozada, L. G.
Right arrow Articles by Johnson, R. J.

Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia

Laura G. Sánchez-Lozada,1 Virgilia Soto,2 Edilia Tapia,1 Carmen Avila-Casado,2 Yuri Y. Sautin,3 Takahiko Nakagawa,3 Martha Franco,1 Bernardo Rodríguez-Iturbe,4 and Richard J. Johnson3

Departments of 1Nephrology and 2Pathology, Instituto Nacional de Cardiología Ignacio Chavez, Mexico City, Mexico; 3Department of Medicine/Nephrology, University of Florida, Gainesville, Florida; and 4Renal Service and Laboratory, Hospital Universitario and Instituto de Investigaciones Biomédicas, Maracaibo, Venezuela

Submitted 28 February 2008 ; accepted in final form 8 August 2008


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Endothelial dysfunction is a characteristic feature during the renal damage induced by mild hyperuricemia. The mechanism by which uric acid reduces the bioavailability of intrarenal nitric oxide is not known. We tested the hypothesis that oxidative stress might contribute to the endothelial dysfunction and glomerular hemodynamic changes that occur with hyperuricemia. Hyperuricemia was induced in Sprague-Dawley rats by administration of the uricase inhibitor, oxonic acid (750 mg/kg per day). The superoxide scavenger, tempol (15 mg/kg per day), or placebo was administered simultaneously with the oxonic acid. All groups were evaluated throughout a 5-wk period. Kidneys were fixed by perfusion and afferent arteriole morphology, and tubulointerstitial 3-nitrotyrosine, 4-hydroxynonenal, NOX-4 subunit of renal NADPH-oxidase, and angiotensin II were quantified. Hyperuricemia induced intrarenal oxidative stress, increased expression of NOX-4 and angiotensin II, and decreased nitric oxide bioavailability, systemic hypertension, renal vasoconstriction, and afferent arteriolopathy. Tempol treatment reversed the systemic and renal alterations induced by hyperuricemia despite equivalent hyperuricemia. Moreover, because tempol prevented the development of preglomerular damage and decreased blood pressure, glomerular pressure was maintained at normal values as well. Mild hyperuricemia induced by uricase inhibition causes intrarenal oxidative stress, which contributes to the development of the systemic hypertension and the renal abnormalities induced by increased uric acid. Scavenging of the superoxide anion in this setting attenuates the adverse effects induced by hyperuricemia.

superoxide; glomerular hypertension; arteriolopathy; tempol; uric acid

REACTIVE OXYGEN SPECIES (ROS) play an important pathophysiological role in the development of hypertension and renal disease (43, 56, 58). The kidney and the vasculature are rich sources of NADPH oxidase-derived ROS, which under pathological conditions decrease the bioavailability of nitric oxide (NO), thus contributing to renal dysfunction and vascular damage (12, 49, 57). Superoxide can react with NO that can deplete the endothelium of this valuable vasodilator; in the process, peroxynitrite is generated, and that by itself is implicated in oxidative and nitrosating reactions (28). Moreover, because the kinetics and thermodynamics of the reaction between superoxide and NO are particularly favorable, the formation of peroxynitrite is inevitable in vivo (46).

On the other hand, uric acid (UA) and ascorbate (vitamin C) are considered the two major antioxidants in plasma (42). Furthermore, the ability of UA to preferentially react with peroxynitrite has been shown to improve certain neurological conditions associated with increased oxidative stress (16, 22, 41). However, the reaction of UA with peroxynitrite can also generate radicals, consistent with the ability of UA to become prooxidative under various circumstances (38). In addition, a frequent finding in humans is a remarkable association of hyperuricemia with hypertension, obesity/metabolic syndrome, kidney disease, and cardiovascular disease (17, 18, 50, 59).

Recent studies (21, 34) revealed that hyperuricemic rats have low plasma NO and suppressed urinary excretion of the final products of NO metabolism (NO2–/NO3–); these abnormalities in endothelial function were in association with renal vasoconstriction, glomerular and arterial hypertension, and preglomerular arteriolopathy. Stimulation of NO synthesis with L-arginine markedly increased urinary NO2–/NO3– (suggesting an increase in endothelial NO production), lowered systemic blood pressure, relieved cortical vasoconstriction, and prevented glomerular hypertension and preglomerular arteriolopathy (34). The mechanism by which UA reduces the availability of intrarenal NO is not known; however, increased oxidative stress could be implicated (39).

In effect, there is accruing evidence that part of the intracellular detrimental effects induced by UA are mediated by oxidative stress; for example, urate-induced monocyte chemoattractant protein 1 (MCP-1) expression in vascular smooth muscle cells was attenuated by antioxidants (19). More recently, we reported (39) that adipocyte differentiation was associated with increased uptake of UA and ROS accumulation; in this setting, increased concentrations of UA in the culture media induced a further increase in intracellular ROS production mediated by activation of NADPH oxidase. Intracellular NADPH oxidase-mediated oxidative stress induced activation of MAP kinases p38 and ERK1/2, an increase in protein nitrosylation and lipid oxidation, and a decrease in NO bioavailability (39). These effects were prevented by probenecid and benzbromarone (urate transport blockers), antioxidants, and NADPH oxidase inhibitors (39). In addition, Corry et al. (6) recently reported that UA induces oxidative stress and a depletion of intracellular NO in rat vascular smooth muscle cells. The reduction of intracellular NO in human vascular (endothelial and vascular smooth muscle cells) has also been reported (20).

We therefore studied the possible contribution of oxidative stress induced by experimental mild hyperuricemia on the development of arterial hypertension and the glomerular hemodynamic changes, as well as the renal microvascular alterations observed in this model. To test this hypothesis, we treated oxonic acid (OA) dosed rats with the superoxide dismutase mimetic tempol and evaluated the glomerular hemodynamics and the microvascular renal damage. In addition, changes in the expression of the markers of oxidative stress (3-NT) and 4-hydroxynonenal (4-HNE) and protein expression of NADPH oxidase subunit NOX-4 and angiotensin II (AII) were quantified.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Three groups of male Sprague-Dawley rats were studied for a total period of 5 wk. To produce hyperuricemia, 14 animals received regular diet and OA (Sigma, St. Louis, MO) at a dose of 750 mg/kg body wt daily by gastric gavage. Seven rats were given Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1 oxyl; catalog no. 176141, Sigma-Aldrich), a stable membrane-permeable superoxide dismutase mimetic (15 mg/kg per day by gastric gavage), simultaneously with OA. An additional group of seven normal rats were studied as normal controls. Experiments were performed in accordance to the Mexican Federal Regulation for animal experimentation and care (NOM-062-ZOO-2001) and were approved by Bioethics and Investigation Committees of Instituto Nacional de Cardiologia Ignacio Chavez.

Measurements. Systolic blood pressure (SBP) was measured in conscious rats by tail cuff sphygmomanometer (XBP-1000; Kent Scientific, Torrington, CT). All animals were preconditioned for blood pressure measurements 1 wk before each experiment. Plasma UA was measured by phosphotungstic acid method (Uricostat, Wiener, Argentina) in all animals at baseline and at the end of 4 wk. In urine samples taken during micropuncture, the excretion of the final products of NO metabolism (NO2–/NO3–) was measured. Samples were first incubated with Escherichia coli nitrate reductase to convert the NO3– to NO2–, as described previously (3, 14). After incubation, total NO2– was measured using the Griess reagent. Known concentrations of NaNO2 and NaNO3 were used as standards in each assay. Data were corrected by whole glomerular filtration rate (GFR) and are expressed as nmol/ml.

Micropuncture. At the end of 5 wk, animals were anesthetized with pentobarbital sodium (30 mg/kg ip) and placed on a thermoregulated table to maintain body temperature at 37°C. Trachea, jugular veins, femoral arteries, and the left ureter were catheterized with polyethylene tubing (PE-240, PE-50, and PE-10). The left kidney was exposed, placed in a Lucite holder, sealed with agar, and covered with Ringer's solution. Mean arterial pressure (MAP) was monitored with a pressure transducer (model no. p23 db; Gould, San Juan, Puerto Rico) connected to the catheter in the femoral artery and recorded on a polygraph (Grass Instruments, Quincy, MA). Blood samples were taken periodically and replaced with blood from a donor rat. Rats were maintained under euvolemic conditions by infusion of 10 ml/kg body wt of isotonic rat plasma during surgery, followed by an infusion of 25% polyfructosan, at 2.2 ml/h (Inutest; Fresenius Kabi, Linz, Austria). After 60 min, five to seven samples of proximal tubular fluid were obtained to determine flow rate and polyfructosan concentrations. Intratubular pressure under free-flow and stop-flow conditions and peritubular capillary pressure (Pc) were measured in other proximal tubules with a servo-null device (Servo Nulling Pressure System; Instrumentation for Physiology and Medicine, San Diego, CA). Glomerular colloid osmotic pressure was estimated from protein concentrations obtained from blood of the femoral artery (Ca) and surface efferent arterioles (Ce). Polyfructosan was measured in plasma and urine samples by the anthrone-based technique of Davidson and Sackner (7). Whole GFR was calculated using the following formula: GFR = (U x V) / P, where U is the polyfructosan concentration in urine, V is urine flow rate, and P is the polyfructosan concentration in plasma.

The volume of fluid collected from individual proximal tubules was estimated from the length of the fluid column in a constant bore capillary tube of known internal diameter. The concentration of tubular polyfructosan was measured by microfluorometric method of Vurek and Pegram (53). Single-nephron glomerular filtration rate (SNGFR) was calculated using the formula: SNGFR = (TF/P)PF x V, where (TF/P)PF is the ratio of concentration of polyfructosan in tubular fluid (TF) and plasma (P), and V is the tubular flow rate that is obtained by timing the collection of tubular fluid (4). Protein concentration in afferent and efferent samples was determined according to the method of Viets et al. (52). MAP, GFR, glomerular capillary hydrostatic pressure (PGC), single-nephron plasma flow (QA), afferent (AR), efferent (ER), and total resistances, and ultrafiltration coefficient (Kf) were calculated using equations previously reported (4).

Renal histology and quantification of morphology. After the micropuncture study at the end of 5 wk, kidneys were washed by perfusion with PBS and fixed with 4% paraformaldehyde. Renal biopsies were embedded in paraffin. Sections (4 µm) of fixed tissue were stained with periodic acid Schiff reagent. Arteriolar morphology was assessed by indirect peroxidase immunostaining for {alpha}-smooth muscle actin (DAKO, Carpinteria, CA). Renal sections incubated with normal rabbit serum were used as negative controls for immunostaining against {alpha}-smooth muscle actin (34, 35, 37).

For each arteriole, the outline of the vessel and its internal lumen (excluding the endothelium) were generated using computer analysis to calculate the total medial area (outline – inline), in 10 arterioles per biopsy. Only vessels in close proximity to glomeruli were evaluated. The media/lumen ratio was calculated by the outline/inline relationship (36). All analyses were performed blinded.

3-NT and 4-HNE, as markers of nitrosative stress and lipid peroxidation, respectively, and NADPH- oxidase NOX-4 subunit as well as AII were quantified by immunohistochemistry and morphometry using the following antibodies: rabbit anti-3-NT polyclonal antibodies (catalog no. 06-284; Upstate, Lake Placid, NY); mouse anti-4-HNE monoclonal antibodies (catalog no. 24325; Oxis International, Portland, OR); rabbit anti-rat NOX-4 polyclonal antibodies (catalog no. ab60940; Abcam, Cambridge, MA); and rabbit anti-rat AII monoclonal antibody (catalog no. T-4007; Bachem, Torrance, CA). In brief, 3-NT, 4-HNE, NOX-4, and AII expression were evaluated by the indirect streptavidin-biotin-peroxidase method and counterstained with periodic acid Schiff PAS. Twenty-five at 400x (3-NT, 4-HNE, and AII) and 25 at 200x (NOX-4) noncrossed fields of cortex per biopsy were analyzed using Image-Pro-Plus 5.0 (Media Cybernetics, Silver Spring, MD). Positive brown color areas were selected and quantified in pixel unit, and the number of positive areas was expressed as pixels/400x or pixels/200x field. The mean value was obtained by averaging the values from all examined fields.

Statistical analysis. Values were expressed as means ± SE. Differences between groups were evaluated by ANOVA with appropriate correction for multiple comparisons (Bonferroni). The relation between variables was assessed by correlation analysis.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
General parameters. Body weight was comparable in all groups of rats at the end of the study [normal (N) = 333 ± 6 g; OA = 353 ± 17 g; and OA + Tempol = 350 ± 7 g], suggesting that tempol treatment did not affect food consumption.

After 5 wk of OA administration, rats developed hyperuricemia (N = 1.2 ± 0.20 mg/dl; OA = 3.33 ± 0.20 mg/dl; P < 0.001 vs. N, Fig. 1) and systemic hypertension (N = 122 ± 2.2 mmHg; OA = 149 ± 4.7 mmHg; P < 0.001 vs. N, Fig. 1) compared with normal control rats (34). The group that received tempol had similar values of UA as the OA control group at the end of Week 4 (UA = 2.96 ± 0.24 mg/dl, P < 0.001 vs. N, P = ns vs. OA, Fig. 1); however, SBP values were significantly lower relative to hyperuricemic rats (131 ± 2.1 mmHg, P < 0.01 vs. OA, Fig. 1).


Figure 1
View larger version (26K):
[in this window]
[in a new window]

  		Fig. 1. Effect of antioxidant therapy with tempol to oxonic acid (OA)-treated rats on uric acid, blood pressure, glomerular filtration rate (GFR), urinary excretion of nitric oxide (NO) metabolites (NO2–/NO3–), single nephron GFR, and glomerular pressure.

 
Glomerular hemodynamics. Urinary excretion of NO2–-NO3– corrected for whole GFR is shown in Fig. 1. In OA group, the excretion of NO stable end products was suppressed compared with normal control rats (N = 5.1 ± 0.6 nmol/ml GFR; OA = 0.30 ± 0.1 nmol/ml GFR, P < 0.001 vs. N, Fig. 1) (34). Chronic treatment with tempol maintained urinary excretion of NO2–/NO3– in values equivalent to the normal group (5.0 ± 1.5, P < 0.01 vs. OA, Fig. 1)

In the hyperuricemic (OA) group, MAP was significantly higher (N = 123 ± 1 mmHg; OA = 149 ± 2 mmHg; P < 0.001), whereas whole GFR tended to be lower compared with normal control animals (N = 0.84 ± 0.1 ml/min; OA + V: 0.66 ± 0.1 ml/min; P = ns) (34). Scavenging of superoxide with tempol partially prevented the rise of MAP (136 ± 5 mmHg, P < 0.01 vs. OA and N) and preserved whole GFR in normal values (0.78 ± 0.1 ml/min).

Hyperuricemic rats developed cortical vasoconstriction as indicated by reduced single nephron GFR (Table 1, Fig. 1) and ultrafiltration coefficient (Table 1); glomerular plasma flow tended to be lower, although it did not reach statistical significance (Table 1) (34). AR and ER increased significantly because of hyperuricemia as well (Table 1) (34). In addition, despite cortical vasoconstriction, hyperuricemic rats suffered glomerular hypertension (Table 1, Fig. 1) (34).


View this table:
[in this window]
[in a new window]

  		Table 1. Glomerular hemodynamics in normal, oxonic acid, and oxonic acid + tempol rats

 
Treatment with tempol prevented glomerular hemodynamic alterations induced by hyperuricemia; single nephron GFR (Table 1, Fig. 1), glomerular plasma flow, ultrafiltration coefficient, afferent and efferent arteriolar resistances (Table 1), and glomerular pressure (Table 1, Fig. 1) remained at normal values.

Afferent arteriole morphology, markers of intrarenal oxidative stress, and NOX-4 and AII renal expression. Figs. 2 and 3 show the results of preglomerular arteriole morphological evaluation and tubulointerstitial markers of oxidative stress. OA-induced hyperuricemia was associated with arteriolar wall thickening (34). Chronic administration of tempol maintained preglomerular vessel morphology similar to normal rats.


Figure 2
View larger version (21K):
[in this window]
[in a new window]

  		Fig. 2. Effect of antioxidant therapy with tempol to OA-treated rats on afferent arteriole morphology, tubulointerstitial markers of oxidative stress, 3-nitrotyrosine (3-NT) and 4-hydroxynonenal (4-HNE), and NOX-4 and angiotensin II (AII) expressions in normal, oxonic acid, and oxonic acid + tempol-treated rats.

 

Figure 3
View larger version (130K):
[in this window]
[in a new window]

  		Fig. 3. Representative micrographs of afferent arteriole morphology, tubulointerstitial markers of oxidative stress, 3-NT and 4-HNE, and NOX-4 and AII expressions in normal, oxonic acid and oxonic acid + tempol-treated rats (all 400x, except NOX-4, 200x).

 
Peroxynitrite can produce novel products such as 3-NT that serve as an important biological marker in vivo (32). Hyperuricemic rats showed an increased immunostaining of 3-NT in tubulointerstitial areas of 2.7 times relative to normal rats. Tempol treatment partially reduced 3-NT immunostaining.

4-HNE is a biologically active aldehyde produced during membrane lipid peroxidation in inflammation and oxidative stress (8). We studied intrarenal lipid peroxide using an anti-4-HNE antibody. Tubulointerstitial staining of 4-HNE was significantly enhanced in OA-treated rats; an increase of 3.9 times relative to normal rats was observed. Scavenging of superoxide radical in hyperuricemic rats improved lipid peroxidation.

Because NOX-4 subunit functions as the catalytic moiety of the NADPH-oxidase enzyme, changes in the expression of this subunit is of utmost importance during physiopathological conditions (26). We selected to evaluate NOX 4 because this isoform is highly expressed in the proximal convoluted tubule cells of the renal cortex (11) and was previously shown that increased levels of UA upregulated the expression of this isoform in adipocytes (39). We observed that NOX-4 immunostaining was increased 2.76 times in hyperuricemic rats relative to normal animals; simultaneous treatment with tempol reduced significantly NOX-4 overexpression.

Previous studies have shown that the intrarenal AII content correlates closely with quantification of renal AII immunostaining by computer image analysis (9). On the other hand, it has been previously shown that OA administration induced the overexpression of renin in juxtaglomerular cells (24), a finding that suggests the possibility that AII synthesis might be increased in hyperuricemic rats. Consistent with this hypothesis, renal AII was significantly increased in hyperuricemic rats; moreover, when we analyzed both normal and OA-dosed rats together, a strong linear correlation between UA and AII was observed (r = 0.89, P < 0.0001). In addition, as was previously reported in cyclosporin A (CsA)-treated rats (27), tempol treatment prevented renal AII overexpression in hyperuricemic rats.

Finally, the following correlations were observed: UA vs. 3-NT (r = 0.56, P = 0.03), urinary excretion of NO2–/NO3– vs. 3-NT (r =–0.66, P = 0.02), NOX-4 vs. 3-NT (r = 0.85, P < 0.0001), AII vs. NOX-4 (r = 0.49, P = 0.03) vs. 4-HNE (r = –0.78, P = 0.002), single nephron GFR vs. 3-NT (r = –0.69, P = 0.005), PGC and 3-NT vs. 4-HNE (r = 0.92, P < 0.0001).


   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
In the present study, we tested the hypothesis that ROS might contribute to the endothelial dysfunction and systemic and renal hemodynamic changes associated with experimentally induced hyperuricemia. This hypothesis was based on cell-culture studies that UA may function as a prooxidant under certain circumstances (6, 19, 39) and the possibility that the reduction in NO could be mediated by an increase in oxidative stress (5).

The principal finding was that OA-induced hyperuricemia triggered intrarenal oxidative stress revealed by significant increments of NOX-4 protein expression, protein nitration, and lipid peroxidation; moreover, these alterations occurred in concert with AII renal overexpression. These findings suggest that the excessive synthesis of ROS contributed to the decreased bioavailability of NO, as was indicated by the suppression of the excretion of NO metabolites, as well as the development of systemic hypertension, renal cortical vasoconstriction, and intrarenal microvascular damage. Chronic scavenging of superoxide with tempol was able to prevent the systemic and renal alterations induced by hyperuricemia despite plasma UA remaining elevated. Moreover, because tempol treatment prevented the development of preglomerular damage and decreased blood pressure, glomerular pressure was maintained at normal values as well.

An imbalance between prooxidants and antioxidants results in oxidative stress, which is the pathogenic consequence of increased oxidant synthesis that overcomes the cellular antioxidant capacity. Superoxide anion can be generated in the kidney by xanthine oxidoreductase (XO) or NADPH oxidase (56). However, both enzymes apparently are regulated differently; for example, in AII-infused rats (54) and during chronic renal disease (51), NADPH oxidase is upregulated, at least in renal cortex; in contrast, XO remain unchanged or is downregulated (51, 54). NADPH oxidase is also upregulated in the kidney of animals with diabetes (31). On the contrary, in the genetic model of essential hypertension [spontaneously hypertensive rats (SHR)], both XO and NADPH oxidase are upregulated (2, 23). Recently we reported that UA was able to stimulate NADPH oxidase with oxidant generation, reduction in NO levels, and the formation of peroxynitrite in cultured adipocytes (39). Moreover MCP-1 upregulation and NF-{kappa}B activation induced by UA have been shown to be inhibited by antioxidants in vascular muscle cells (19) and proximal tubular cells, respectively (15). A new finding resulting from the present studies was that mild hyperuricemia induced a significant increase of NOX-4 protein expression in kidney, as was previously observed in adipocytes (39), suggesting that increased production of superoxide radical derived from this enzyme may have a role in the renal damage induced by hyperuricemia. However, we cannot rule out the participation of different sources of oxygen radicals in this pathology.

One potential mechanism by which UA might induce oxidative stress could be by stimulation of the renin angiotensin system (RAS). Corry et al. (6) also recently demonstrated that UA stimulated proliferation, AII production, and oxidative stress and decreased NO bioavailability in vascular smooth muscle cells; these effects were prevented by the administration of losartan or captopril, suggesting that they are mediated by the activation of RAS. We have also reported that hyperuricemia activates the intrarenal RAS in rodents (24); in this model, the administration of enalapril improved systemic hypertension, renal structural damage, and preglomerular arteriolopathy in hyperuricemic rats (24, 25). Toma et al. (48) have also reported that UA causes immediate renin release, utilizing an elegant afferent arteriole-isolated glomerular preparation. Furthermore, hyperuricemia is closely linked to elevated plasma renin activity in humans (30). In turn, AII is a strong activator of renal and vascular NADPH oxidase (33); this fact suggests that superoxide-mediated oxidative stress during hyperuricemia likely resulted from the direct and/or indirect activation of intrarenal NADPH oxidase. In effect, in the present study, we found that hyperuricemia induced a significant increment of intrarenal AII expression; furthermore, a strong linear correlation between UA and AII was noted when the analysis included both normal and OA-dosed groups (r = 0.89, P < 0.0001). Interestingly, it has been reported that tempol increased the expression of renin in SHR (55); in contrast it prevented the increment in the expression of renal AII in CsA-treated rats through an unknown mechanism (27). In the present studies, we confirmed that tempol prevented the intrarenal overexpression of AII in OA-dosed rats. In addition, we found a mild but positive correlation between AII and NOX-4 (r = 0.49, P = 0.03). These findings suggest that AII is partially mediating the increment in the expression of NOX-4; however, it is likely that other mechanisms are participating as well.

Several studies suggest that the increased production of superoxide is implicated in the decreased bioavailability of NO in several experimental models of renal damage and hypertension as well as in human hypertension (10, 40, 47, 54). A reliable approach to detect the interaction between NO and superoxide is the formation of peroxynitrite, which can be evaluated by documenting the presence of 3-NT residues (32). In our studies, increased immunostaining of 3-NT in hyperuricemic rats suggests that endothelial dysfunction is related to the excessive production of superoxide; moreover, we found a correlation between UA and 3-NT (r = 0.56, P = 0.03) and negative correlations between urinary excretion of NO2–/NO3– with 3-NT (r = –0.66, P = 0.02) and with 4-HNE (r = –0.78, P = 0.002).

In the present report as well as in a previous study (34), we reported an unusually suppressed urinary excretion of NO metabolites in OA-treated rats. A possible explanation for this outcome is that NO3–/NO2– metabolites are extensively reabsorbed in the proximal tubule (45) but with the maintenance of a linear relationship between plasma NO3–/NO2– levels and its urinary excretion rate (13). Interestingly, plasma concentrations of sodium nitrate in the lowest range were associated with the lowest fractional excretion and the highest tubular reabsorption rates (13). Since it was previously shown that OA-dosed rats have decreased plasma concentrations of NO metabolites in plasma (21), its tempting to speculate that increased tubular reabsorption rates of nitrates occurred in hyperuricemic animals, resulting in an almost suppressed excretion of this metabolite in this condition.

The reaction of NO with superoxide has been shown to limit the relaxing effect of the former on afferent arterioles (54). In the present study, the scavenging of superoxide with tempol prevented the development of renal vasoconstriction in hyperuricemic rats; in addition, a negative correlation between 3-NT and single nephron GFR was observed (r = –0.69, P = 0.005). We previously showed that supplementation of L-arginine (NO synthase substrate) to hyperuricemic rats augmented the synthesis of NO (34); that effect likely overcame the increased production of superoxide, improving renal vasoconstriction.

Another marker of increased oxidative stress is lipid peroxidation (8). Hyperuricemic rats showed increased immunostaining of 4-HNE. In this regard, there are reports indicating that UA is able to amplify the oxidation of lipids (1, 29); moreover, in cultured adipocytes, UA was associated with the oxidation of membrane lipids secondary to the activation of NADPH oxidase (39). On the other hand, peroxynitrite is a potent oxidation species that has been found to cause lipid peroxidation per se (32). In the present study, treatment with tempol to hyperuricemic rats significantly reduced the immunostaining of 4-HNE; furthermore, we found a strong positive correlation between the renal immunostaining of 3-NT and 4-HNE (r = 0.92, P < 0.0001).

We have reported that one of the main mechanisms associated with the renal damage induced by hyperuricemia is the alteration of autoregulatory capacity in preglomerular vessels that allows the transmission of systemic hypertension to glomerular capillaries (34–37); this defect is linked to the microvascular lesion induced by UA in the afferent arteriole (25). Glomerular pressure is regulated by the relative contribution of AR and ER as well as by arterial pressure. Thus glomerular hypertension may result from a proportional increment of ER relative to AR, or alternatively due to an inadequate autoregulatory response of AR to an increment in systemic pressure. In the present study, we observed that both normal and OA-dosed animals had the same ER/AR ratio (normal 0.55 ± 0.03, OA 0.56 ± 0.03), indicating a similar level of ER relative to AR in both groups. In contrast, we observed a mild but significant linear relationship between both systolic and MAP vs. glomerular pressure (SBP vs. PGC r = 0.45, P = 0.04; MAP vs. PGC r = 0.48, P = 0.02). This finding suggests the transmission of systemic hypertension to glomerular capillaries, as was previously reported by us in hyperuricemic rats and by others in fawn-hooded rats (44). Thus, in OA-treated rats, we have the unusual situation of renal vasoconstriction and afferent arteriolopathy coexisting with glomerular hypertension. In the present study, antioxidant therapy to hyperuricemic rats prevented the rise of glomerular pressure; this beneficial effect was likely the consequence of the preservation of the integrity of preglomerular vessels and a lower systemic pressure.

In conclusion, mild hyperuricemia is associated with intrarenal oxidative stress, which contributes to the development of the systemic hypertension and the renal abnormalities induced by increased UA. Moreover, scavenging of superoxide anion attenuated the adverse effects induced by increased UA. Further studies will be necessary to determine the relevance of these findings in the setting of hyperuricemia-associated cardiovascular and renal diseases in humans.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by the National Council of Science and Technology (CONACyT), Mexico, Grant 52021/66778 (to L. Sanchez-Lozada) and NIH grant HL-68607 (to L. Sanchez-Lozada, Y. Sautin, T. Nakagawa, and R. Johnson).


   ACKNOWLEDGMENTS
 
We thank Jose Santamaría, Magdalena Cristóbal, Armando Medina-Cruz, and Benito Chávez-Rentería for technical assistance.


   FOOTNOTES
 

Address for reprint requests and other correspondence: L. Gabriela Sánchez-Lozada, Dept. of Nephrology. INC Ignacio Chávez, Juan Badiano 1. 14080. Mexico City, Mexico (e-mail: lgsanchezlozada{at}gmail.com)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 446: 305–308, 1999.[CrossRef][Web of Science][Medline]
  2. Adler S, Huang H. Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol Renal Physiol 287: F907–F913, 2004.[Abstract/Free Full Text]
  3. Bartholomew B. A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of Escherichia coli. Food Chem Toxicol 22: 541–543, 1984.[CrossRef][Web of Science][Medline]
  4. Baylis C, Deen WM, Myers BD, Brenner BM. Effects of some vasodilator drugs on transcapillary fluid exchange in renal cortex. Am J Physiol 230: 1148–1158, 1976.[Abstract/Free Full Text]
  5. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840–844, 2000.[Abstract/Free Full Text]
  6. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26: 269–275, 2008.[Web of Science][Medline]
  7. Davidson WD, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 62: 351–356, 1963.[Web of Science][Medline]
  8. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81–128, 1991.[CrossRef][Web of Science][Medline]
  9. Franco M, Martinez F, Quiroz Y, Galicia O, Bautista R, Johnson RJ, Rodriguez-Iturbe B. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 293: R251–R256, 2007.[Abstract/Free Full Text]
  10. Fujii S, Zhang L, Igarashi J, Kosaka H. L-arginine reverses p47phox and gp91phox expression induced by high salt in Dahl rats. Hypertension 42: 1014–1020, 2003.[Abstract/Free Full Text]
  11. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97: 8010–8014, 2000.[Abstract/Free Full Text]
  12. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 8: 1597–1607, 2006.[CrossRef][Web of Science][Medline]
  13. Godfrey M, Majid DS. Renal handling of circulating nitrates in anesthetized dogs. Am J Physiol Renal Physiol 275: F68–F73, 1998.[Abstract/Free Full Text]
  14. Granger DL, Hibbs JB Jr, Perfect JR, Durack DT. Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest 85: 264–273, 1990.[Web of Science][Medline]
  15. Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-{kappa}B. Am J Physiol Renal Physiol 292: F373–F381, 2007.[Abstract/Free Full Text]
  16. Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, Spitsin SV. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14: 691–698, 2000.[Abstract/Free Full Text]
  17. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44: 642–650, 2004.[CrossRef][Web of Science][Medline]
  18. Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W, Roncal C, Sanchez-Lozada LG, Gersch M, Rodriguez-Iturbe B, Kang DH, Acosta JH. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 16: 1909–1919, 2005.[Abstract/Free Full Text]
  19. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41: 1287–1293, 2003.[Abstract/Free Full Text]
  20. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16: 3553–3562, 2005.[Abstract/Free Full Text]
  21. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 67: 1739–1742, 2005.[CrossRef][Web of Science][Medline]
  22. Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 49: 139, 2001.[CrossRef][Web of Science][Medline]
  23. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, Lapatto R. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 22: 1333–1340, 2004.[CrossRef][Web of Science][Medline]
  24. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101–1106, 2001.[Abstract/Free Full Text]
  25. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991–F997, 2002.[Abstract/Free Full Text]
  26. Nauseef WM. Biological roles for the NOX family NADPH oxidases. J Biol Chem 283: 16961–16965, 2008.[Free Full Text]
  27. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, Hitomi H, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 42: 754–760, 2003.[Abstract/Free Full Text]
  28. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315–424, 2007.[Abstract/Free Full Text]
  29. Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 44: 512–521, 2003.[Abstract/Free Full Text]
  30. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 66: 1465–1470, 2004.[CrossRef][Web of Science][Medline]
  31. Prabhakar S, Starnes J, Shi S, Lonis B, Tran R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 18: 2945–2952, 2007.[Abstract/Free Full Text]
  32. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 101: 4003–4008, 2004.[Abstract/Free Full Text]
  33. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 18: 2439–2446, 2007.[Abstract/Free Full Text]
  34. Sanchez-Lozada LG, Tapia E, Lopez-Molina R, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol 292: F1238–F1244, 2007.[Abstract/Free Full Text]
  35. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67: 237–247, 2005.[CrossRef][Web of Science][Medline]
  36. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, Johnson RJ. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 83: 1179–1185, 2008.
  37. Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283: F1105–F1110, 2002.[Abstract/Free Full Text]
  38. Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 372: 285–294, 1999.[CrossRef][Web of Science][Medline]
  39. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293: C584–C596, 2007.[Abstract/Free Full Text]
  40. Schneider MP, Delles C, Schmidt BM, Oehmer S, Schwarz TK, Schmieder RE, John S. Superoxide scavenging effects of N-acetylcysteine and vitamin C in subjects with essential hypertension. Am J Hypertens 18: 1111–1117, 2005.[CrossRef][Web of Science][Medline]
  41. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99: 16303–16308, 2002.[Abstract/Free Full Text]
  42. Sevanian A, Davies KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am J Clin Nutr 54: 1129S–1134S, 1991.[Medline]
  43. Shah SV. Oxidants and iron in chronic kidney disease. Kidney Int Suppl S50–S55, 2004.
  44. Simons JL, Provoost AP, Anderson S, Rennke HG, Troy JL, Brenner BM. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 46: 396–404, 1994.[Web of Science][Medline]
  45. Suto T, Losonczy G, Qiu C, Hill C, Samsell L, Ruby J, Charon N, Venuto R, Baylis C. Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int 48: 1272–1277, 1995.[Web of Science][Medline]
  46. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6: 662–680, 2007.[CrossRef][Web of Science][Medline]
  47. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 97: 2222–2229, 1998.[Abstract/Free Full Text]
  48. Toma I, Kang JJ, Meer EJ, Peti-Peterdi J. Uric acid triggers renin release via a macula densa-dependent pathway (Abstract). J Am Soc Nephrol 18, 156A. 2007.
  49. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44: 248–252, 2004.[Abstract/Free Full Text]
  50. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 55: 1293–1301, 2006.[CrossRef][Web of Science][Medline]
  51. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63: 179–185, 2003.[CrossRef][Web of Science][Medline]
  52. Viets JW, Deen WM, Troy JL, Brenner BM. Determination of serum protein concentration in nanoliter blood samples using fluorescamine or 9-phthalaldehyde. Anal Biochem 88: 513–521, 1978.[CrossRef][Web of Science][Medline]
  53. Vurek G, Pegram S. Fluorometric method for the determination of nanogram quantities of inulin. Anal Biochem 16: 409–419, 1966.[CrossRef][Web of Science]
  54. Wang D, Chen Y, Chabrashvili T, Aslam S, Borrego Conde LJ, Umans JG, Wilcox CS. Role of oxidative stress in endothelial dysfunction and enhanced responses to angiotensin II of afferent arterioles from rabbits infused with angiotensin II. J Am Soc Nephrol 14: 2783–2789, 2003.[Abstract/Free Full Text]
  55. Welch WJ, Mendonca M, Blau J, Karber A, Dennehy K, Patel K, Lao YS, Jose PA, Wilcox CS. Antihypertensive response to prolonged tempol in the spontaneously hypertensive rat. Kidney Int 68: 179–187, 2005.[CrossRef][Web of Science][Medline]
  56. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 289: R913–R935, 2005.[Abstract/Free Full Text]
  57. Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4: 160–166, 2002.[Web of Science][Medline]
  58. Wilcox CS, Gutterman D. Focus on oxidative stress in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 288: H3–H6, 2005.[Free Full Text]
  59. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rhee EJ, Lee WY, Kim SW, Ryu SH, Keum DG. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69: 928–933, 2005.[CrossRef][Web of Science][Medline]



This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Shimada, R. J. Johnson, W. S. May Jr, V. Lingegowda, P. Sood, T. Nakagawa, Q. C. Van, B. Dass, and A. A. Ejaz
A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome
Nephrol. Dial. Transplant., October 1, 2009; 24(10): 2960 - 2964.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/4/F1134    most recent
00104.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sánchez-Lozada, L. G.
Right arrow Articles by Johnson, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sánchez-Lozada, L. G.
Right arrow Articles by Johnson, R. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.